Laxmi Therapeutic Devices, Inc.

Laxmi Therapeutic Devices, Inc. has raised $54.3M in total funding.

Laxmi Therapeutic Devices, Inc. is headquartered in Goleta, CA.

Laxmi will help people with diabetes stay in range more often, supporting better day-to-day control and long-term health through industry-first dermal continuous glucose monitoring.

Existing glucose monitoring has lag time that limits how much patients can stay in their target glucose range, and lower time-in-range is linked to higher risk of eye and kidney disease progression, especially during fast changes like meals, exercise, or pregnancy.

Laxmi is building a continuous glucose monitoring system (sensor, transmitter, and applicator) that measures glucose in the dermal skin layer and sends real-time readings to a phone or reader via Bluetooth.

They describe their dermal sensing as an 'industry first,' claiming the dermis's vascular support enables faster-tracking glucose signals than typical sensing, and cite their own published research using the FDA-approved UVA/Padova Type 1 Diabetes Simulator linking reduced lag time to improved time-in-range.

Founded in 2016, the Goleta-based wearable diabetes-monitoring device maker counts the U.S. Department of Health and Human Services among its funders alongside venture investors.